Pembrolizumab – November 2021

• Brand names:
  • Keytruda®
• Pharmaceutical Company:
  • Merck Sharp & Dohme (Australia) Pty Ltd
• Condition/Indication: Squamous cell carcinoma of the head and neck (SCCHN)
• Meeting Date: November 2021
• Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1776KB)
• Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 501KB)

Related Public Summary Documents

• Pembrolizumab – November 2020
• Pembrolizumab – March 2022